Ekso Bionics Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 15 - Net Loss Per Share (Tables)

Note 15 - Net Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2024

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

		*Three Months Ended*								*Six Months Ended*
		*June 30,*								*June 30,*
		*2024*				*2023*				*2024*				*2023*
Numerator:
Net loss applicable to common stockholders, basic and diluted		$	(2,416	)		$	(4,230	)		$	(5,845	)		$	(8,619	)

Denominator:
Weighted-average number of shares, basic and diluted			18,224				13,637				17,822				13,467

Net loss per common share, basic and diluted		$	(0.13	)		$	(0.31	)		$	(0.33	)		$	(0.64	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

		*Three Months Ended*								*Six Months Ended*
		*June 30,*								*June 30,*
		*2024*				*2023*				*2024*				*2023*
Options to purchase common stock			192				261				192				261
Restricted stock units			1,082				1,555				1,082				1,555
Warrants for common stock			1,047				1,240				1,047				1,240
Total common stock equivalents			2,321				3,056				2,321				3,056